Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | -0.25% | 40.00 | 0.9% | $1281.75m | |
| JNJ | Johnson & Johnson | 0.14% | 170.19 | 0.7% | $1253.43m | |
| MRK | Merck & Co., Inc. | -0.60% | 78.22 | 0.7% | $926.88m | |
| ABBV | AbbVie, Inc. | -0.07% | 116.52 | 1.9% | $721.02m | |
| BMY | Bristol-Myers Squibb Co. | -0.31% | 64.84 | 1.0% | $719.56m | |
| LLY | Eli Lilly & Co. | 0.75% | 196.40 | 1.1% | $573.53m | |
| AZN | AstraZeneca Plc | 0.29% | 55.21 | 1.2% | $531.67m | |
| BTX | Brooklyn ImmunoTherapeutics, Inc. | -7.43% | 21.69 | 12.8% | $256.18m | |
| GSK | GlaxoSmithKline Plc | 1.11% | 39.09 | 0.2% | $191.43m | |
| NVS | Novartis AG | 0.68% | 89.00 | 0.2% | $173.64m | |
| VTRS | Viatris, Inc. | 0.44% | 16.00 | 0.0% | $168.43m | |
| CVAC | CureVac NV | 7.47% | 109.99 | 0.0% | $159.75m | |
| NVO | Novo Nordisk A/S | 0.28% | 79.11 | 0.1% | $72.19m | |
| SNY | Sanofi | 0.38% | 52.74 | 0.2% | $71.76m | |
| ATNX | Athenex, Inc. | 3.25% | 5.08 | 0.0% | $62.70m |
Company Profile
Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.